Carbohydrate receptor mimicry as a basis for anti-infective therapy

Current Opinion in Drug Discovery and Development

Volumn 3, Issue 2, 2000, Pages 191-202

  Armstrong, Glen D ^a  

^a UNIVERSITY OF ALBERTA   (Canada)

Author keywords

Anti adhesive; Antibiotic; Antimicrobial; Bacterial adhesion; Carbohydrate receptors; Resistance

Indexed keywords

ANTIINFECTIVE AGENT; CARBOHYDRATE DERIVATIVE; RECEPTOR;

ANTIBIOTIC RESISTANCE; ANTIMICROBIAL ACTIVITY; BACTERIAL COLONIZATION; BACTERIUM ADHERENCE; CLOSTRIDIUM DIFFICILE; ESCHERICHIA COLI; HELICOBACTER PYLORI; PSEUDOMONAS AERUGINOSA; REVIEW;

EID: 0034004939     PISSN: 13676733     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (100)

1. Vestweber D, Blanks JEMechanisms that regulate the function of the selectins and their ligands. Physiol Rev (1999)79:181-213.
2. Paulson JCCarbohydrate ligands of leukocyte adhesion molecules and their therapeutic potential. Prog Brain Res (1994)101:179-184.
3. Kim CU, Chen X, Mendel DBNeuraminidase inhibitors as anti-influenza virus agents. Antiviral Chem Chemother (1999)10:141-154.
4. Colacino JM, Staschke KA, Laver WGApproaches and strategies for the treatment of influenza virus infections. Antiviral Chem Chemother (1999) 10:155-185.
5. Goss PE, Baker MA, Carver JP. Dennis JW: Inhibitors of carbohydrate processing: A new class of anticancer agents. Clin Cancer Res (1995) 9:935-944.
6. Beachey EHBacterial adherence: Adhesin-receptor interactions mediating the attachment of bacteria to mucosal surface. J Infect Dis (1981) 143:325-345.
7. Bock K, Karlsson K-A, Strömberg N, Teneberg SInteraction of viruses, bacteria and bacterial toxins with host cell surface glycolipids. Aspects on receptor identification and dissection of binding epitopes. Adv Exp Med Bio! (1988) 228:153-186.
8. Yates AJ, Rampersaud ASphingolipids as receptor modulators. An overview. Ann NY Acad Sd (1998) 845:57-71.
9. Balfanz J, Rautenberg P, Ullmann UMolecular mechanisms of action of bacterial exotoxins. Zentralbl Bakteriol (1996) 284:170-206.
10. Bastiaens PI, Majoul IV, Verveer PJ, Söling HD, Jovin TMImaging the intracellular trafficking and state of the AB, quaternary structure of cholera toxin. EMBO J (1996) 15:4246-4253.
11. Ghose ACAdherence and colonization properties of Vibrio cholerae and diarrhoeagenic Escherichia coli. Indian J Med Research (1996) 104:38-51.
12. Karlsson K-AGlycobiology: A growing field for drug design. Trends Pharmacol Sci ( 1991) 12:265-272.
13. Aronson M, Medalia O, Schon L, Mirelman D, Sharon N, Ofek lPrevention of colonization of the urinary tract of mice with Escherichia coli by blocking of bacterial adherence with methyl a-D-mannopyranoside. J Infect Dis (1979) 139:329-332.
14. Nataro JP, Kaper JBDiarrheagenic Escherichia coli. Clin Microbiol Re v (1998) 11:142-201.
15. DeVinney R, Stein M, Reinscheid D, Abe A, Ruschkowski S, Finlay BBEnterohemorrhagic Escherichia coli O157:H7 produces Tir, which is translocated to the host cell membrane but is not tyrosine phosphorylated. Infect Immun (1999) 67:2389-2398.
16. O'Brien AD, Tesh VL, Donohue-Rolfe A, Jackson MP, Olsnes S, Sandvig K, Lindberg AA, Keusch GTShiga toxin: Biochemistry, genetics, mode of action, and role in pathogenesis. Curr Top Microbiol Immunot (1992) 180:65-94.
17. Sjogren R, Neill R, Rachmilewitz D, Fritz D, Newland J, Sharpnack D, Colleton C, Fondacaro J, Gemski P, Boedeker ERole of Shiga-like toxin I In bacterial enteritis: Comparison between isogenic Escherlchia coll strains induced in rabbits. Gastroenterology (1994) 106:306-317.
18. Rowe PC, Orrbine E, Lior H, Wells GA, Yetisir E, Clulow M, McLaine PNRisk of hemolytic urémie syndrome after sporadic Escherlchia coll O157:H7 infection: Results of a Canadian collaborative study. JPediatr (1998) 132:777-782.
19. Cimolai N, Carter JE, Morrison BJ, Anderson JDRisk factors for the progression of Escherichia co//O157:H7 enteritis to hemolytic-uremic syndrome. J Pediatr (1990) 116:589-592.
20. Karmali MA, Pétrie M, Lim C, Fleming PC, Arbus GS, Lior HThe association between idiopathic hemolytic-uremic syndrome and Infection by verotoxin-producing Escherichia coll. J Infect Dis (1985) 151:775-782.
21. Stein PE, Boodhoo A, Tyrrell GJ, Brunton JL, Read RJCrystal structure of the cell-binding B oligomer of verotoxin-1 from E coli. Nature (1992) 355:748-750.
22. Lingwood CAVerotoxins and their glycolipld receptors. Adv Lipid Res (1993) 25:189-211.
23. Ling H, Boodhoo A, Hazes B, Cummings MD, Armstrong GD, Brunton JL, Read RJStructure of the shiga-like toxin I Bpentamer complexed with an analogue of its receptor Gb,. Biochemistry (199S) 37:1777-1788.
24. Armstrong GD, Fodor E, Vanmaele RInvestigation of shigalike toxin binding to chemically synthesized oligosaccharide sequences. J Infect Dis (1991) 164:11 GO1167.
25. Lemieux RU, Bundle DR, Baker DAThe properties of a 'synthetic' antigen related to the human blood-group Lewis A. JAm Chem Soc (1975) 97:4076-4083.
26. Armstrong GD, Rowe PC, Goodyer P, Orrbine E, Klassen TP, Wells G, MacKenzie A, Lior H, Blanchard C, Auclair F, Thompson B, Rafter DJ, McLaine PNA phase I study of chemically synthesized verotoxin (Shiga-like toxin) Pktrisaccharide receptors attached to Chromosorb for preventing hemolytic-uremic syndrome. J Infect Dis (1995) 171:1042-1045.
27. Armstrong GD, McLaine PN, Rowe PCClinical trials of Synsorb-Pk in preventing hemolytic-uremic syndrome. In:
28. Escherichia coli O157:H7 and other Shiga toxin-producing E coli strains. Kaper JB, O'Brien AD (Eds), American Society for Microbiology, Washington DC, USA (1998):374-384.
29. Hurley BP, Jacewicz M, Thorpe CM, Lincicome LL, King AJ, Keusch GT, Acheson DWShiga toxins 1 and 2 translocate differentially across polarized intestinal epithelial cells. Infect Immun (1999) 67:6670-6677.
30. Weis Wl, Drickamer KStructural basis of lectin-carbohydrate recognition. Annu RevBiochem (1996) 65:441-473.
31. Bundle DR, Young NMCarbohydrate-protein Interactions in antibodies and lectins. Curr Opin Struct Biol (1992) 2:666673.
32. Kartsson K-AAnimal glycosphingolipids as membrane attachment sites for bacteria. Annu Rev Biochem (1989) 58:309-350.
33. Nyholm PG, Magnusson G, Zheng 2, Norel R, Binnington-Boyd B, LJngwood CATwo distinct binding sites for globotriaosyl ceramide on verotoxins: Identification by molecular modeling and confirmation using deoxy analogues and a new glycolipid receptor for all verotoxins. Chem Biol (1996) 3:263-275.
34. Mammen M, Choi S-K, Whitesides GMPolyvalent interactions in biological systems: Implications for design and use of multivalent ligands and inhibitors. Angew Chem Int Ed Engl (1998) 37:2754-2794.
35. Mylvaganam M, Lingwood CAAdamantyl globotriaosyl ceramide: A monovalent soluble mimic which inhibits verotoxin binding to its glycolipid receptor. Biochem Biophys Res Commun (1999) 257:391-394.
36. Kitov PI, Sadowska JM, Mulvey G, Armstrong GD, Ling H, Pannu NS, Read RJ, Bundle DRShiga-like toxins are neutralized by tailored multivalent carbohydrate ligands. Nature (2000) 403:669-672.
37. Bast DJ, Banerjee L, Clark C, Read RJ, Brunton JLThe identification of three biologically relevant globotriosyl ceramide receptor binding sites on the Verotoxin 1 B subunit Mol Microbiol C9Q9) 32:953-960.
38. Shimizu H, Reld RA, Homans SW, Donohue-Rolfe ASolution structure of the complex between the B-subunit homopentamer of verotoxin VT-1 from Escherichia coli and the trisaccharide moiety of globotriaosylceramide. Biochemistry (1998) 37:11078-11082.
39. Girön JA, Ho ASY, Schoolnik GKCharacterization of fimbriae produced by enteropathogenic Escherichia coll. J Bacteno/(1993) 175:7391-7403.
40. Frankel G, Phillips AD, Rosenshine l, Dougan G, Kaper JB, Knutton SEnteropathogenic and enterohaemorrhagic Escherichia coir. More subversive elements. Mol Microbiol (1998)30:911-921.
41. Finlay BB, Falkow SCommon themes in microbial pathogenicity revisited. Microbiol Mol Biol Rev (1997) 61:136-169.
42. Vanmaele RP, Heerze LD, Armstrong GDRole of lactosyl glycan sequences In inhibiting enteropathogenic Escherichia coli attachment Infect Immun (1999) 67:33023307.
43. Crane JK, Azar SS, Stam A, Newburg DSOligosaccharides from human milk block binding and activity of the Escherichia coli heat-stable enterotoxin (STa) in T84 intestinal cells. JNutr(1d94) 124:2358-2364.
44. Jagannatha HM, Sharma UK, Ramaseshan T, Surolia A, Balganesh TSIdentification of carbohydrate structures as receptors for localized adherent enteropathogenic Escherichia coli. Microb Pathog (1991) 11:259-268.
45. Neeser JR, Koellreutter B, Wuersch POligomannoslde-type glycopeptides inhibiting adhesion of Escherichia coli strains mediated by type 1 pili: Preparation of potent inhibitors from plant glycoproteins. Infect Immun (1986) 52:428-436.
46. Cravioto A, Tello A, Villafân H, Ruiz J, Del Vedovo S, Neeser J-RInhibition of localized adhesion of enteropathogenic Escherichia coll to HEp-2 cells by immunoglobulin and oligosaccharide fractions of human colostrum and breast milk. J Infect Dis (1991) 163:1247-1255.
47. Knutton S, Adu-Bobie J, Bain C, Phillips AD, Dougan G, Frankel GDownregulation of intimin expression during attaching and effacing enteropathogenic Escherichia coll adhesion. Infect Immun (1997) 65:1644-1652.
48. Zhang JP, Normark SInduction of gene expression in Escherichia coli after pilus mediated adherence. Science (1996)273:1234-1236.
49. Mitchell HMThe epidemiology of Helicobacter pylori. Curr Top Microbiol Immunol (1999) 241:11 -30.
50. Dunn BE, Cohen H, Blaser MJHelicobacter pylori. Clin Microbiol Rev (1997) 10:720-741.
51. Ge Z, Taylor DEContributions of genome sequencing to understanding the biology of Helicobacter pylori. Annu Rev Microbiol(Q9ff) 53:353-387.
52. Danesh JHelicobacter pylori Infection and gastric cancer: Systematic review of the epidemiological studies. Aliment Pharmacol Therapeut (1999) 13:851-856.
53. Houben MH, Van Der Beek D, Hensen EF, Craen AJ, Rauws EA, Tytgat GNA systematic review of Helicobacter pylori eradication therapy - the impact of antimicrobial resistance on eradication rates. Aliment Pharmacol Therapeut (1999) 13:1047-1055.
54. Su B, Hellstrom PM, Rubio C, Celik J, Granstrom M, Normark SType I Helicobacter pylori shows Lewis(b)-independent adherence to gastric cells requiring de novo protein synthesis in both host and bacteria. J Infect Dis (1998) 178:1379-1390.
55. Doig P, Trust TJThe molecular basis for H pylori adherence and colonization. In: The Immunobiology of H pylori: From Pathogenesis to Prevention. Ernst PB, Michetti P, Smith PD (Eds), Lippincott-Raven, PA, USA (1997):47-57.
56. Wang G, Rasko DA, Sherbume R, Taylor DEMolecular genetic basis for the variable expression of Lewis Y antigen In Helicobacter pylori: Analysis of the a (1,2) fucosyltransferase gene. Mol Microbiol (1999) 31:1265-1274.
57. Taylor DE, Rasko DA, Sherbume R, Ho C, Jewell LDLack of correlation between Lewis antigen expression by Hellcobacter pylori and gastric epithelial cells in infected patients. Gastroenterology (1998) 115:1113-1122.
58. Simon PM, Goode PL, Mobasseri A, Zopf DInhibition of Helicobacter pylori binding to gastrointestinal epithelial cells by sialic acid-containing oligosaccharides. Infect Immun (1997) 65:750-757.
59. Quinn JPClinical problems posed by multiresistant nonfermenting Gram-negative pathogens. Clin Infect Dis (1998) 27(Suppl1):S117-S124.
60. Hancock REResistance mechanisms in Pseudomonas aeruginosa and other non-fermentative Gram-negative bacteria. Clin Infect Dis (1998) 27(Suppl 1):S93-S99.
61. Bryan R, Feldman M, Jawetz SC, Rajan S, DiMango E, Tang HB, Scheffler L, Speert DP, Prince AThe effects of aerosolized dextran in a mouse model of Pseudomonas aeruginosa pulmonary infection. J Infect Dis (1999) 179:1449-1458.
62. Feng W, Garrett H, Speert DP, King MImproved clearability of cystic fibrosis sputum with dextran treatment in vitro. Am J Respir Crit Care Med (1998) 157:710-714.
63. Surawicz CM, McFarland LVPseudomembranous colitis: Causes and cures. Digestion (1999) 60:91-100.
64. Bordello SPPathogenesis of Clostridium difficile infection. JAntimicrob Chemother(1998) 41(Suppl C):13-19.
65. Wilcox MHTreatment of Clostridium difficile infection. J Antimicrob Chemother (1998) 41 (Suppl C):41 -46.
66. Lewis SJ, Freedman ARReview article: The use of biotherapeutic agents in the prevention and treatment of gastrointestinal disease. Aliment Pharmacol Therapeut (1998)12:807-822.
67. Elmer GW, Surawicz CM, McFarland LVBiotherapeutic agents. A neglected modality for the treatment and prevention of selected intestinal and vaginal infections. J Am MedAssoc (1996) 275:870-876.
68. Gorenek L, Dizer U, Besirbellioglu B, Eyigun CP, Hacibektasoglu A, Van Thiel DHThe diagnosis and treatment of Clostridium difficile in antibiotic-associated diarrhea. Hepatogastroenterology (1999) 46:343-348.
69. Liacouras CA, Piccoli DAWhole-bowel irrigation as an adjunct to the treatment of chronic, relapsing Clostridium difficile colitis. J Clin Gastroenterol (1996) 22:186-189.
70. Giannasca PJ, Zhang ZX, Lei WD, Boden JA, Giel MA, Monath TP, Thomas WDSerum antitoxin antibodies mediate systemic and mucosal protection from Clostridium difficile disease in hamsters. Infect Immun (1999) 67:527-538.
71. Ward SJ, Douce G, Figueiredo D, Dougan G, Wren BWImmunogenicity of a Salmonella typhimurium aroA aroD vaccine expressing a non-toxic domain of Clostridium difficile toxin A. Infect Immun (1999) 67:2145-2152.
72. Ward SJ, Douce G, Dougan G, Wren BWLocal and systemic • neutralizing antibody responses induced by intranasal immunization with the non-toxic binding domain of toxin A from Clostridium difficile. Infect Immun (1999) 67:5124-5132.
73. Krivan HC, Clark GF, Smith DF, Wilkïns TDCell surface binding site for Clostrldium difficile enterotoxin: Evidence for a glycoconjugate containing the sequence Gal a 1-3Gal 1-4GlcNAc. Infect Immun (1986) 53:573-581.
74. George WLAntimicrobial agent-associated colitis and diarrhea: Historical background and clinical aspects. Rev Infect Dis (1984) 6(Suppl 1):S208-S213.
75. Bongaerts GP, Lyerly DMRole of toxins A and B in the pathogenesis of Clostridium difficile disease. Microb Pathog (1994) 17:1 -12.
76. Burakoff R, Zhao L, Celifarco AJ, Rose KL, Donovan V, Pothoulakis C, Percy WHEffects of purified Clostridium difficile toxin A on rabbit distal colon. Gastroentemlogy (1995) 109:348-354.
77. Fonteles M, Fang G, Thielman NM, Yotseff PS, Guerrant RLRole of platelet activating factor In the inflammatory and secretory effects of Clostridium difficile toxin A. J Lipid Médiat Cell Signal (1995) 11:133-143.
78. Mahida YR, Makh S, Hyde S, Gray T, Borriello SPEffect of Clostridium difficile toxin A on human intestinal epithelial cells: Induction of interleukin 8 production and apoptosis after cell detachment Gut (1996) 38:337-347.
79. Mantyh CR, Maggio JE, Mantyh PW, Vigna SR, Pappas TNIncreased substance P receptor expression by blood vessels and lymphoid aggregates in Clostridium difficileInduced pseudomembranous colitis. Dig Dis Sci (1996) 41:614-620.
80. Wershil BK, Castagliuolo I, Pothoulakis CDirect evidence of mast cell involvement in Clostridium difficile toxin A-induced enteritis in mice. Gastroentemlogy (1998) 114:956-964.
81. Heerze LD, Keim MA, Talbot JA, Armstrong GDOligosaccharide sequences attached to an inert support (SYNSORB) as potential therapy for antibiotic-associated diarrhea and pseudomembranous colitis. J Infect Dis (1994) 169:1291-1296.
82. Castagliuolo I, LaMont JT, Qiu B, Nikulasson ST, Pothoulakis CA receptor decoy inhibits the enterotoxic effects of Clostridium difficile toxin A in rat ileum. Gastroenterotogy (1996)111:433-438.
83. Castagliuolo l, Riegler MF, Valenick L, LaMont JT, Pothoulakis CSaccharomyces boulardii protease inhibits the effects of Clostridium difficile toxins A and B in human colonie mucosa. Infect Immun (1999) 67:302-307.
84. Wren BWA family of clostridial and streptococcal ligandbinding proteins with conserved C-terminal repeat sequences. Mol Microbiol(1991) 5:797-803.
85. Masoud HM, Perry MB, Brisson J-R, Uhn'n D, Richards JCStructural elucidation of the backbone Oligosaccharide from the lipopolysaccharide of Moraxella catarrhalis serotype A. Can J Chem (1994) 72:1466-1476.
86. Perry MB, MacLean LLStructural characterization of the Opolysaccharide produced by Salmonella milwaukee O:43 (group U) which possesses human blood group B activity. Biochem Cell Biol (1991) 70:49-55.
87. Perry MB, MacLean LLStructure of the polysaccharide Oantigen of Salmonella riogrande O:40 (group R) related to blood group A activity. Carbohydr Res (1992) 232:143-150.
88. Schriemer DC, Hindsgaul ODeconvolution approaches in screening compound mixtures. Comb Chem HighThroughput Screen (1998) 1:155-170.
89. Minke WE, Roach C, Hol WG, Verlinde CLStructure-based exploration of the ganglioside GM1 binding sites of Escherichia coll heat-labile enterotoxin and cholera toxin for the discovery of receptor antagonists. Biochemistry (1999)38:5684-5692.
90. Kenny BA, Bushfield M, Parry-Smith DJ, Fogarty S, Treheme JMThe application of high-throughput screening to novel lead discovery. Prog Drug Res (1998) 51:245-269.
91. Lemmo AV, Rose DJ, Tisone TCInkJet dispensing technology: Applications in drug discovery. Curr Opin Biotechnol (1998) 9:615-617.
92. Zopf D, Roth SOligosaccharide anti-infective agents. Lancet (1996) 347:1017-1021.
93. Nilsson UJ, Heerze LD, Liu Y-C, Armstrong GD, Palcic MM, Hindsgau! OImmobilization of reducing sugars as toxin binding agents. Bioconjug Chem (1997) 8:466-471.
94. Katoh T, Honda T, Miwatani TPurification and some properties of cytotoxin produced by Clostridium difficile. Microbiol Immunol (1988) 32:551-564.
95. THE HOSPITAL FOR SICK CHILDREN RESEARCH AND DEVELOPMENT LP (Lingwood CA, Mylvaganam MGlycolipid mimics and methods of use thereof. US-05973128 (1999).
96. NEOSE TECHNOLOGIES INC (Zopf DA, Simon PM, Roth S, McGuire EJ, Langer DHMethod for inhibiting H pylori infection in mammalian tissue. US-05883079 (1999).
97. SYNSORB BIOTECH INC (Heerze LD, Armstrong GDMethod of binding and removing toxin A. US-05635606 (1997).
98. SYNSORB BIOTECH INC (Heerze LD, Armstrong GDTreatment of C difficile toxin B associated conditions. US-06013635 (2000).
99. SYNSORB BIOTECH INC (Hindsgaul OCombinatorial synthesis of carbohydrate libraries. US-05965719 (1999).
100. SYNSORB BIOTECH INC (Hindsgaul O, Nilsson UJSolid support matrices containing a toxin binding Oligosaccharide. US-06013634 (2000).